Glucagonoma risk factors: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
(Mahshid) |
||
| Line 18: | Line 18: | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Surgery]] | |||
Latest revision as of 01:49, 27 November 2017
|
Glucagonoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Glucagonoma risk factors On the Web |
|
American Roentgen Ray Society Images of Glucagonoma risk factors |
|
Risk calculators and risk factors for Glucagonoma risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2], Mohammed Abdelwahed M.D[3]
Overview
The most common risk factor in the development of glucagonoma is a positive family history of multiple endocrine neoplasia type1 which is characterized by the presence of pituitary adenomas, islet cell tumors of the pancreas, and hyperparathyroidism.
Risk Factors
- The most common risk factor in the development of glucagonoma is a positive family history of multiple endocrine neoplasia type 1.[1][2]
- It is an autosomal dominant syndrome that is usually caused by mutations in the MEN1 gene.
- It is characterized by the development of the following tumors:[1]
- Pituitary adenomas
- Islet cell tumors of the pancreas (commonly gastrinoma and glucagonoma)
- Parathyroid hyperplasia with resulting hyperparathyroidism
References
- ↑ Afsharfard A, Atqiaee K, Lotfollahzadeh S, Alborzi M, Derakhshanfar A (2012). "Necrolytic migratory erythema as the first manifestation of glucagonoma". Case Rep Surg. 2012: 974210. doi:10.1155/2012/974210. PMC 3434377. PMID 22970401.
- ↑ Glucagonoma. U.S. National Library of Medicine. https://www.nlm.nih.gov/medlineplus/ency/article/000326.htm